BTH, I can be reached at aspenmontana@msn.com caravon PS It is of interest that Tiva behaves in NSCLC c-MET low pts similar to Avastin in breast cancers, i.e., a very solid PFS improvement and no OS benefits. I intend to raise this issue with ARQL's CMO.